快讯| Editas Medicine Inc - 至少在2027年前提交一个IND/CTA 快讯6分钟前 快讯| Editas Medicine强调新的体内临床前概念数据、预期的2025年关键里程碑和三年战略优先事项 快讯7分钟前 新闻稿:Editas Medicine 强调新的体内临床前概念板块数据、预期2025年的关键里程碑以及三年战略优先事项 Editas Medicine强调了新的体...
EDIT Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced -81.52% Editas Medicine, Inc. price and volume Combination chart with 2 data series. Chart represents Editas Medicine, Inc. price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has ...
公司名称Editas Medicine 上市日期2016/02/03 发行价格16.00 成立日期2013 CEODr. Gilmore O’Neill, M.B. 所属市场纳斯达克 员工数量265 年结日12-31 公司地址11 Hurley Street 城市Cambridge 省份马萨诸塞州 国家美国 邮编02141 电话1-617-401-9000 网址http://www.editasmedicine.com 董事高管 姓名 职务 年...
The emotional state of those investors is what determines the price for Editas Medicine. If more investors feel that the Editas Medicine Stock will rise, it most likely will increase; and if more investors feel that the Editas price will fall, then it will fall. Thus, a stock's price ...
Editas Medicine, Inc. (EDIT) growth grade and underlying metrics. Quant Ratings, revenue growth, EBITDA, EPS, cash flow, ROE, compounded, charts, and stocks comparison.
EDITStockUSD1.210.021.63% Editas Medicine pattern recognition tool provides the execution environment for running the Counterattack recognition and other technical functions against Editas Medicine. Editas Medicine value trend is the prevailing direction of the price over some defined period of time. The ...
Topics discussed include increase in stock market of biotechnology company Editas Medicine Inc. which offers genome editing technology, medical device Tandem Diabetes Care Inc. increases after its upgraded shares, decrease in Peregrine Pharmaceuticals Inc. after announcing it is discontinuing its trial of...
作者: $Editas Medicine, Inc. Common Stock(EDIT)$已经涨到40,超过了之前所有投资机构的目标价
$Editas Medicine, Inc. Common Stock(EDIT)$ 无可否认,张锋确实是一位生物学领域的天才,关键是他还很年轻,很拼命,有抱负,有商业头脑。同为生物学界的科研人员,张锋确实是我们领域的明星。
Editas MedicineandVertex Pharmaceuticalshave forged a$50 million dealfor a licensing agreement of Editas’s Cas9 technology. In an announcement on Wednesday, Editas said Vertex will get a non-exclusive license the gene editing tech for use in medicines that target the BCL11A gene in sickle cell...